Ibex and Sana Kliniken Berlin-Brandenburg partner to bring AI-powered cancer diagnostics to Germany

7 Jul, 2021

Back

Sana Kliniken Berlin-Brandenburg will deploy Ibex’s AI-powered Galen™ platform, helping pathologists provide accurate diagnosis and improved care for cancer patients

Tel Aviv, Israel, and Berlin, Germany, July 7, 2021 – Ibex Medical Analytics, the pioneer in artificial intelligence (AI) -powered cancer diagnostics and Sana Kliniken Berlin-Brandenburg, part of Sana Kliniken AG – the third largest private hospital group in Germany, today announced the first deployment and clinical evaluation in Germany of an AI platform that supports pathologists during routine cancer diagnosis.

Pathologists play a crucial role in the detection and diagnosis of disease, with their assessments being vital for reaching correct treatment decisions by oncologists. However, a rise in cancer prevalence and advances in personalized medicine have resulted in growing diagnostic complexity that significantly increases pathologists’ workloads. In recent years, as pathology labs transition towards digital solutions, pathologist can implement AI enhanced workflows to improve quality and efficiency of cancer diagnosis, resulting in better patient care.

Ibex transforms cancer diagnosis by harnessing Strong AI and machine learning technology at an unprecedented scale. Ibex’s Galen platform helps pathologists improve the quality of cancer diagnosis, implement real-time quality control1, reduce diagnosis time and boost productivity2. It is CE marked for breast and prostate cancer detection in multiple workflows and was recently granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). Galen has already demonstrated outstanding outcomes in clinical studies3,4 and has been deployed in labs worldwide where it is used as part of everyday clinical practice.

The Sana Klinikum Lichtenberg is the major hospital of the Sana Kliniken Berlin-Brandenburg. It operates the largest certified colorectal cancer centre in the Berlin area, as well as certified cancer centres for pancreatic, gastric, breast and gynecological cancers. Sana is currently digitizing its pathology labs using Philips’ IntelliSite Pathology Solution5, deploying a network of high-throughput digital pathology scanners, an image management system and an integrated lab information system. As part of the partnership with Ibex, pathologists at Sana will use the Galen platform as part of routine practice and evaluate the clinical impact of using AI during diagnosis of multiple tissue types in various workflows.

“Quality diagnosis delivered on-time is paramount for us at Sana, and we are committed to continually improving the processes in our lab,” said Prof. Gerald Niedobitek, MD, Head of Pathology at the Sana Klinikum Berlin-Lichtenberg. “We were among the pioneers in adopting digital pathology in Germany and are proud to be among the first laboratories in the country to implement artificial intelligence in routine diagnostic pathology. We look forward to working closely with Ibex on demonstrating the clinical benefits of AI and how it can help improve patient care.”

“We are excited to team up with Sana Kliniken Berlin-Brandenburg and empower their pathologists with AI-powered solutions to more accurately detect cancer and improve quality and efficiency of diagnosis,” said Stuart Shand, Chief Commercial Officer at Ibex Medical Analytics. “This partnership further proves Sana’s commitment to its patients, leading by example to ensure the best possible outcomes. Artificial intelligence and digital pathology technologies are becoming the new standard in cancer care, a mission both Sana and Ibex are proud to be part of.”

Back

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.